Russia’s flagship two-shot vaccine Sputnik V has shown 91.6 per cent efficacy against symptomatic Covid-19 in clinical trials, a Lancet peer review has confirmed, bringing the global total of vaccines whose efficacy is confirmed to be higher than 90 per cent to three.
經《柳葉刀》(Lancet)同行評審確認，俄羅斯的旗艦疫苗、需要接種兩劑的「衛星-V”(Sputnik V)在臨牀試驗中對預防有症狀新型冠狀病毒肺炎（COVID-19，即2019冠狀病毒病）的有效率達到91.6%，從而使全球有效率經確認高於90%的疫苗總數增加到三種。
您已閱讀9%（402字），剩餘91%（4082字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。